SCOPUS 정보 검색 플랫폼

Volumn 20, Issue 1, 2002, Pages 83-93

Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies

(20) Schellens, J H M a Heinrich, B b Lehnert, M c Gore, M E d Kaye, S B e Dombernowsky, P f Paridaens, R g Van Oosterom, A T g Verweij, J h Loos, W J h Calvert, H i Pavlidis, N j Cortes Funes, H k Wanders, J l Roelvink, M l Sessa, C m Selinger, K n Wissel, P S n Gamucci, T o Hanauske, A R g

a NETHERLANDS CANCER INSTITUTE (Netherlands)

b TECHNICAL UNIVERSITY OF MUNICH (Germany)

c CANTONAL HOSPITAL ST GALLEN (Switzerland)

d INSTITUTE OF CANCER RESEARCH (United Kingdom)

e BEATSON WEST OF SCOTLAND CANCER CENTRE (United Kingdom)

f GENTOFTE UNIVERSITY HOSPITAL (Denmark)

g UNIVERSITY HOSPITALS LEUVEN (Belgium)

h ERASMUS MEDICAL CENTER (Netherlands)

i NEWCASTLE GENERAL HOSPITAL (United Kingdom)

more..

Author keywords

Bayesian algorithm; Lurtotecan (GI147211); NONMEM; Pharmacodynamics; Pharmacokinetics; Phase II; Population analysis; Topoisomerase I

Indexed keywords

CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; LURTOTECAN;

ADULT; AGED; ARTICLE; BAYES THEOREM; CLINICAL TRIAL; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; SAMPLING STUDIES;

EID: 0036210568 PISSN: 01676997 EISSN: None Source Type: Journal
DOI: 10.1023/A:1014454821885 Document Type: Article

Times cited : (10)

References (26)

1
- 0024316466
- DNA topoisomerase poisons as antitumor drugs
- (1989) Ann Rev Biochem , vol.58 , pp. 351-375
- Liu, L.F.¹

2
- 0004158996
- Cozzarelli NR, Wang JC, eds. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
- (1990) DNA topology and its biological effects
- Wang, J.C.¹ Liu, L.F.²

3
- 0028267240
- Camptothecins: From bench research to hospital wards
- (1994) Cancer Res , vol.54 , pp. 1431-1439
- Potmesil, M.¹

4
- 0032489675
- A model for the mechanism of human topoisomerase 1
- (1998) Science , vol.279 , pp. 1534-1541
- Stewart, L.¹ Redinbo, M.R.² Qiu, X.³ Hol, W.G.J.⁴ Champoux, J.J.⁵

5
- 0025812689
- Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA
- (1991) Nucleic Acids Res , vol.19 , pp. 3295-3300
- Ryan, A.J.¹ Squires, S.² Strutt, H.L.³ Johnson, R.T.⁴

6
- 0028033906
- Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors
- (1994) Cancer Investig , vol.12 , pp. 430-542
- Pommier, Y.¹ Leteurtre, F.² Fesen, M.R.³ Fujimori, A.⁴ Bertrand, R.⁵ Solary, E.⁶ Kohlhagen, G.⁷ Kohn, K.W.⁸

7
- 0030826929
- Topoisomerase I inhibitors: Review and update
- (1997) Ann Oncol , vol.8 , pp. 837-855
- Rothenberg, M.L.¹

8
- 0030027405
- Emerging drug treatments for solid tumours
- (1996) Drugs , vol.51 , pp. 45-72
- Schellens, J.H.M.¹ Pronk, L.C.² Verweij, J.³

9
- 0029928849
- Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily ×5 intravenous administration
- (1996) Br J Cancer , vol.73 , pp. 744-750
- Gerrits, C.J.H.¹ Creemers, G.J.² Schellens, J.H.M.³ Wissel, P.⁴ Planting, A.S.T.⁵ Kunka, R.⁶ Selinger, K.⁷ De Boer-Dennert, M.⁸ Marijnen, Y.⁹ Harteveld, M.¹⁰ Verweij, J.¹¹

10
- 15644373056
- Phase I and pharmacokinetic study of GF147211, a water-soluble camptothecin analogue administered five consecutive days every three weeks
- (1998) Clin Cancer Res , vol.4 , pp. 595-604
- Eckhardt, S.G.¹ Baker, S.D.² Eckhardt, J.R.³ Burke, T.G.⁴ Warner, D.L.⁵ Kuhn, J.G.⁶ Rodriguez, G.⁷ Fields, S.⁸ Thurman, A.⁹ Smith, L.¹⁰ Rothenberg, M.L.¹¹ White, L.¹² Wissel, P.¹³ Kunka, R.¹⁴ Littlefield, D.¹⁵ Burris, H.A.¹⁶ Von Hoff, D.¹⁷ Rowinsky, E.K.¹⁸

11
- 9844250206
- The bioavailability of oral GI146211 (GG211), a new topoisomerase I inhibitor
- (1997) Br J Cancer , vol.76 , pp. 946-951
- Gerrits, C.J.H.¹ Schellens, J.H.M.² Creemers, G.J.³ Wissel, P.⁴ Planting, A.S.T.⁵ Pritchard, J.F.⁶ DePee, S.⁷ De Boer-Dennert, M.⁸ Harteveld, M.⁹ Verweij, J.¹⁰

12
- 0022405120
- Premarketing observational studies of population pharmacokinetics of new drugs
- (1985) Clin Pharmacol Ther , vol.38 , pp. 481-487
- Sheiner, L.B.¹ Benet, L.Z.²

13
- 0004074388
- Brussels, Belgium, Commission of European Communities
- (1992) New strategies in drug development and clinical evaluation: The population approach
- Rowland, M.¹ Aarons, L.²

14
- 0026504422
- Conference report: Opportunities for integration of pharmacokinetics, pharmacodynamics and toxicokinetics in rational drug development
- (1992) Clin Pharmacol Ther , vol.51 , pp. 465-473
- Peck, C.C.¹ Barr, W.H.² Bennet, L.Z.³ Collins, J.⁴ Desjardins, R.E.⁵ Furst, D.E.⁶ Harter, J.G.⁷ Levy, G.⁸ Ludden, T.⁹ Rodman, J.H.¹⁰

15
- 0030064911
- The use of population pharmacokinetics in drug development
- (1996) Clin Pharmacokinet , vol.30 , pp. 81-93
- Vozeh, S.¹ Steimer, J.L.² Rowland, M.³ Morselli, P.⁴ Mentre, F.⁵ Balant, L.⁶ Aarons, L.⁷

16
- 0028970499
- Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum likelihood estimation
- (1995) Cancer Chemother Pharmacol , vol.37 , pp. 47-54
- Launay-Iliadia, M.C.¹ Bruno, R.² Cosson, V.³ Vergniol, J.C.⁴ Oulid-Aissa, D.⁵ Marty, M.⁶ Clavel, M.⁷ Aapro, M.⁸ Le Bail, N.⁹ Iliadia, A.¹⁰

17
- 0031982748
- Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer
- (1998) J Clin Oncol , vol.16 , pp. 187-196
- Bruno, R.¹ Hille, D.² Riva, A.³ Vivier, N.⁴ Ten Bokkel Huinink, W.W.⁵ Van Oosterom, A.T.⁶ Kay, S.B.⁷ Verweij, J.⁸ Fossella, F.V.⁹ Valero, V.¹⁰ Rigas, J.R.¹¹ Seidman, A.D.¹² Chevallier, B.¹³ Fumoleau, P.¹⁴ Burris, H.A.¹⁵ Ravdin, P.M.¹⁶ Sheiner, L.B.¹⁷

18
- 0029800979
- Docetaxel serum protein binding with high affinity to alphalacid glycoprotein
- (1996) Invest New Drug , vol.14 , pp. 147-151
- Urien, S.¹ Barré, J.² Morin, C.³ Paccaly, A.⁴ Montay, G.⁵ Tillement, J.P.⁶

19
- 0028797459
- High-performance liquid chromatographic analysis of the lactone and carboxylate forms of a topoisomerase I inhibitor (the antitumor drug GI147211) in plasma
- (1995) J Chromatogr , vol.663 , pp. 119-126
- Stafford, C.G.¹ St. Claire III, R.L.²

20
- 0019604592
- Some suggestions for measuring predictive performance
- (1981) J Pharmacokinet Biopharmaceut , vol.9 , pp. 503-512
- Sheiner, L.B.¹ Beal, S.L.²

21
- 0003747347
- San Francisco, CA, University of California at San Francisco
- (1988) NONMEM. User's guide part I to VI
- Beal, S.L.¹ Boeckman, A.J.² Sheiner, L.B.³

22
- 0019785890
- Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models
- (1981) Clin Pharmacokinet , vol.6 , pp. 242-247
- Holford, N.H.¹ Sheiner, L.B.²

23
- 0026095849
- Designs for population pharmacodynamics: Value of pharmacokinetic data and population analysis
- (1991) J Pharmacokinet Biophar , vol.19 , pp. 333-335
- Hashimoto, Y.¹ Sheiner, L.B.²

24
- 0026717337
- Population pharmacokinetics/dynamics
- (1992) Ann Rev Pharmacol Toxicol , vol.32 , pp. 185-190
- Sheiner, L.B.¹ Ludden, T.M.²

25
- 0031056424
- Phase I and pharmacologic study of oral topotecan administered twice daily for 21-days to adult patients with solid tumors
- (1997) J Clin Oncol , vol.15 , pp. 1087-1093
- Creemers, G.J.¹ Gerrits, C.J.H.² Eckardt, J.R.³ Schellens, J.H.M.⁴ Burris, H.A.⁵ Planting, A.S.T.⁶ Rodriguez, G.I.⁷ Loos, W.J.⁸ Hudson, I.⁹ Broom, C.¹⁰ Verweij, J.¹¹ Von Hoff, D.D.¹²

26
- 0028796513
- Pharmacokinetics and pharmacodynamics of topotecan administered in a daily times five regimen every three weeks
- (1995) Cancer Chemother Pharmacol , vol.35 , pp. 237-245
- Van Warmerdam, L.J.C.¹ Verweij, J.² Schellens, J.H.M.³ Rosing, H.⁴ Davies, B.E.⁵ De Boer-Dennert, M.⁶ Maes, R.A.A.⁷ Beijnen, J.H.⁸

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.